PO-04-223 ASSOCIATION BETWEEN ANTIPARASITIC TREATMENT AND VENTRICULAR ARRYTHMIAS IN PATIENTS WITH CHAGAS DISEASE

Benznidazole and Nifurtimox are the two currently available antiparasitic treatments for Chagas disease (CD), an important cause of cardiomyopathy arrhythmias. There limited data describing impact treatment on arrhythmia outcomes. Compare incidence ventricular arrhythmias in patients treated with anti-parasitic medication versus those who did not receive treatment. Patients at a center excellence were retrospectively analyzed ambulatory rhythm monitoring (Holter 14-day patch monitor). implantable cardiac devices excluded. Significant defined as either PVC burden >/=1% or non-sustained tachycardia (NSVT) ≥4 beats. based CD treatment: Benznidazole, Nifurtimox, no incomplete courses excluded from analysis. A Fisher exact test was used to compare categorical variables. 191 between 12/2014 8/2022 analysis, whom 66 underwent monitoring. Of these, 20 male 46 female average age 55.3 ± 12.6 years, ejection fraction 56.7 10.5%. patients, 42 (63.6%) received treatment, 22 (33.3%) had 2 (3.0%) CD. Among that CD, 11/42 (26.2%) significant In comparison, among 12/22 (54.5%) (p = 0.031). No difference number observed (7/29, 24.1%) (4/12, 33.3%) groups. These demonstrate is associated reduction Further studies needed determine if can lead reduced sudden death.